



Mohamed Helmy <helmy.m@gmail.com>

Query publications

Rasjel van der Holst <R.van.der.Holst@iospress.nl>
To: "helmy.m@gmail.com" <helmy.m@gmail.com>

14 January 2021 at 01:16

Dear Dr. Helmy,

We have been in touch with the author Dr. Kandiah. He confirms that the same disclosures as listed in other articles are non-applicable to the latest articles published in the *Journal of Alzheimer's Disease*. If anything remains unclear, we suggest that further inquiries can be directly taken up either with the corresponding author of the articles directly, or their department.

With best regards,

Rasjel van der Holst
Publisher

<http://www.j-alz.com>; Sign up for the JAD Newsletter

<http://www.facebook.com/journalad>; https://twitter.com/journal_ad



IOS Press

Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands

r.holst@iospress.nl; Tel.: +31 20 688 33 55; www.iospress.com

Begin forwarded message:

From: Mohamed Helmy <helmy.m@gmail.com>
Date: December 16, 2020 at 6:45:16 PM CST
To: George Perry <George.Perry@utsa.edu>
Cc: editorial@j-alz.com
Subject: Re: [EXTERNAL] Query publications

Dear Professor Perry,

Thank you for your message, I am following up on the matter. As Kandiah, N. has at least five (5) recent publications with *Journal of Alzheimer's Disease*, this journal is where the record may need to be corrected most for disclosures by this author.

Kind regards,

Mohamed Helmy

MD, PhD

helmy.m@gmail.com

+65 83 555 817

10 Jurong Lake Link, #15-39

Singapore 648131

On Thu, 17 Dec 2020 at 06:04, George Perry <George.Perry@utsa.edu> wrote:

You should direct the inquiry to the author

George Perry, PhD

Professor

Semmes Foundation Distinguished University Chair in Neurobiology

The University of Texas at San Antonio

Office:210-458-8660

On Dec 15, 2020, at 2:17 AM, Mohamed Helmy <helmy.m@gmail.com> wrote:

****EXTERNAL EMAIL****

This email originated outside of The University of Texas at San Antonio.
Please exercise caution when clicking on links or opening attachments.

Dear Dr. Perry,

cc Kumar, B.

Regarding disclosure and conflict of interest statements for Kandiah, N. in some articles published in *Journal of Alzheimer's Disease* and recently: no disclosure or conflict of interest were declared [1-3]. However for the same author, field of research, and comparable period of time, conflict of interest and/or financial disclosure were declared also in *Journal of Alzheimer's Disease* [4, 5], as well as other journals [6-10]. May the financial disclosure and conflict of interest declaration by Kanidah, N. in *Journal of Alzheimer's Disease* be clarified?

Kind regards,

Mohamed Helmy

MD, PhD

helmy.m@gmail.com

+65 83 555 817

10 Jurong Lake Link, #15-39

Singapore 648131

- [1] Low, A., Ng, K.P., Chander, R.J., Wong, B., & Kandiah, N. Association of Asymmetrical White Matter Hyperintensities and Apolipoprotein E4 on Cognitive Impairment. *Journal of Alzheimer's Disease*. **70**, 953-964 (2019).
- [2] Wong, B.Y.X., Yong, T.T., Lim, L., Tan, J.Y., Ng, A.S.L., Ting, S.K.S., Hameed, S., Ng, K.P., Zhou, J.H., & Kandiah, N. Medial temporal atrophy in amyloid-negative amnesic type dementia is associated with high cerebral white matter hyperintensity. *Journal of Alzheimer's Disease*. **70**, 99-106 (2019).
- [3] Guevarra, A.C., Ng, S.C., Saffari, S.E., Wong, B.Y.X., Chander, R.J., Ng, K.P., & Kandiah, N. Age Moderates Associations of Hypertension, White Matter Hyperintensities, and Cognition. *Journal of Alzheimer's Disease*. **75**, 1351-1360 (2020).
- [4] Vipin, A., Foo, H.J.L., Lim, J.K.W., Chander, R.J., Yong, T.T., Ng, A.S.L., Hameed, S., Ting, S.K.S., Zhou, J., & Kandiah, N. Regional white matter hyperintensity influences grey matter atrophy in mild cognitive impairment. *Journal of Alzheimer's Disease*. **66**, 533-549 (2018).
- [5] Lim, L., Zhang, A., Lim, L., Choong, T.-M., Silva, E., Ng, A., & Kandiah, N. High caregiver burden in young onset dementia: what factors need attention? *Journal of Alzheimer's Disease*. **61**, 537-543 (2018).
- [6] Wong, F.C.C., Yatawara, C., Low, A., Foo, H., Wong, B.Y.X., Lim, L., Wang, B., Kumar, D., Ng, K.P., & Kandiah, N. Cerebral Small Vessel Disease Influences Hippocampal Subfield Atrophy in Mild Cognitive Impairment. *Translational Stroke Research*. 10.1007/s12975-020-00847-4 (2020).
- [7] Wang, B.Z., Zailan, F.Z., Wong, B.Y.X., Ng, K.P., & Kandiah, N. Identification of novel candidate autoantibodies in Alzheimer's disease. *European Journal of Neurology*. 10.1111/ene.14290 (2020).
- [8] Low, A., Yatawara, C., Yong, T.T., Chander, R.J., Ng, K.P., & Kandiah, N. Predictors And Patterns of Cognitive Decline Differ between Mild Cognitive Impairment in Parkinson's Disease (PD-MCI) And Alzheimer's Disease (AD-MCI). *Journal of Alzheimer's Parkinsonism & Dementia, Scient Open Access*. https://www.researchgate.net/profile/Audrey_Low2/publication/331036536_Predictors_And_Patterns_of_Cognitive_Decline_Differ_between_Mild_Cognitive_Impairment_in_Parkinson's_Disease_PD-MCI_And_Alzheimer's_Disease_AD-MCI/links/5c7fe2b992851c69505c4f24/Predictors-And-Patterns-of-Cognitive-Decline-Differ-between-Mild-Cognitive-Impairment-in-Parkinsons-Disease-PD-MCI-And-Alzheimers-Disease-AD-MCI.pdf (2019).
- [9] Lo, J.W., Crawford, J.D., Desmond, D.W., Godefroy, O., Jokinen, H., Mahinrad, S., Bae, H.-J., Lim, J.-S., Köhler, S., Douven, E., Staals, J., Chen, C., Xu, X., Chong, E.J., Akinyemi, R.O., Kalaria, R.N., Ogunniyi, A., Barbay, M., Roussel, M., Lee, B.-C., Srikanth, V.K., Moran, C., Kandiah, N., Chander, R.J., Sabayan, B., Jukema, J.W., Melkas, S., Erkinjuntti, T., Brodaty, H., Bordet, R., Bombois, S., Hénon, H., Lipnicki, D.M., Kochan, N.A., & Sachdev, P.S. Profile of and risk factors for poststroke cognitive impairment in diverse ethnoregional groups. *Neurology*. **93**, e2257-e2271 (2019).

[10] Kandiah, N., Ong, P.A., Yuda, T., Ng, L.-L., Mamun, K., Merchant, R.A., Chen, C., Dominguez, J., Marasigan, S., Ampil, E., Nguyen, V.T., Yusoff, S., Chan, Y.F., Yong, F.M., Krairit, O., Suthisisang, C., Senanarong, V., Ji, Y., Thukral, R., & Ihl, R. Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761®. *CNS Neuroscience & Therapeutics*. **25**, 288-298 (2019).